|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 2 | Delayed stimulatory effect of low - intensity shock waves on human periostealcells 显示文摘 | Tam KF Cheung WH Lee KM | 2005 | Clin Orthop Relat Res2005，438，： | 1 |
| 3 | Delayed stimulatory effect of low-intensity shock wave on human periosteal ceils 显示文摘 | Tam KF Cheung WH Lee KM | 2005 | Clin Orthop Relat Res2005，438，： | 1 |
| 4 | Delayed stimulatory effcet of low-intensity shockwave on human periosteal cell显示文摘 | Tam KF Cheung WH Lee KM | 2005 | Clin Orthop Relat Res2005，438，： | 1 |
| 5 | Association of mitral annular calcification and aortic valve morphology:a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study显示文摘 | Jassal DS Tam JW Bhagirath KM | | 0，，12： | 1 |
| 6 | Hypoglycorrhachia in herpes zoster associated 显示文摘 | CHAN CW TAM KM TO WK | 2005 | J Neuro12005，252，8： | 1 |
| 7 | Responses of preterm infants to hepatitis B vaccine 显示文摘 | Lau YL Tam AY Ng KM | 1992 | J Pediatr1992，121，6： | 1 |
| 8 | Association between RANTES functional polymorphisms and tuberculosis in Hong Kong Chinese显示文摘 | Chu SF Tam CM VCong HS Kam KM Lau YL Chiang AK | 2007 | Genes lmmun2007，8，6： | 1 |
| 9 | Osteogenic effects of low-intensity pulsed ultrasound, extracorporeal shockwaves and their combination-an in vitro comparative study on human periosteal cells 显示文摘 | Tam KF Cheung WH Lee KM | 2008 | Ultrasound Med Bid2008，34，12： | 1 |
| 10 | Responses of preterm infants to hepatitis B vaccine显示文摘 | Lau YL Tam AY Ng KM | 1992 | J Pediatr1992，121，6： | 1 |
| 11 | Delayed stimulatory effect of low-intensity shockwaves on human periosteal cells显示文摘 | Tam KF Cheung WH Lee KM | 2005 | Clinical Orthopaedics Related Research2005，438，： | 1 |
| 12 | The in vivo and in vitro diabetic wound healing effects of a 2-herb formula and its mechanisms of action 显示文摘 | Tam JC Lau KM Li CL | 2011 | J Ethnopharmacol2011，134，3： | 1 |
| 13 | Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: final report显示文摘 | Tam CM Chan SL Kam KM | 2002 | Int J Tuberc Lung Dis2002，6，： | 1 |
| 14 | Shockwave exerts osteogenic effect on osteoporotic bone in an ovariectomized goat mode 显示文摘 | Tam KF Cheung WH Lee KM | 2009 | Ultrasound Med Biol2009，35，： | 1 |
| 15 | Delayed stimulatory effect of low-intensity shockwaves on human periosteal cells显示文摘 | Tam KF Cheung WH Lee KM Qin L Leung KS | | 0，，： | 1 |
| 16 | Delayed stimulatory effect of low-intensity shockwaves on human periosteal ceils 显示文摘 | Tam KF Cheung WH Lee KM | 2005 | Clin Orthop Rel Res2005，438，： | 1 |
| 17 | The in vivo and in vitro diabetic wound healing effects of a 2-herb formula and its mechanisms of action显示文摘 | Tam JC Lau KM Liu CL | 2011 | J Ethnopharmacol2011，134，3： | 1 |
| 18 | Hypoglycorrhachia in herpes zoster associated encephalitis of an immunocompetent young male, an unusual presntation 显示文摘 | Chan CW Tam KM To WK | 2005 | J Neurol2005，252，8： | 1 |
| 19 | Delayed stimulatory effect of low-intensity shockwaves on human periosteal cells显示文摘 | Tam KF Cheung WH Lee KM | 2005 | Clinl Orthop Rel Res2005，438，2： | 1 |
| 20 | Socio-demographic and geographic indicators and distribution of tuberculosis in t-long Kong: a spatial analysis 显示文摘 | Chan-yeung M Yeh AG Tam CM Kam KM Leung CC Yew WW Lain CW | 2005 | Int J TubercLung Dis2005，9，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员